Teva Pharmaceutical Industries Limited (NYSE:TEVA) had its target price reduced by equities research analysts at Barclays PLC from $38.00 to $23.00 in a note issued to investors on Monday. The firm currently has an “equal weight” rating on the stock. Barclays PLC’s price objective would indicate a potential upside of 11.65% from the stock’s current price.

Several other equities research analysts have also recently issued reports on TEVA. Vetr upgraded shares of Teva Pharmaceutical Industries Limited from a “buy” rating to a “strong-buy” rating and set a $37.48 target price on the stock in a report on Tuesday, April 11th. Zacks Investment Research upgraded shares of Teva Pharmaceutical Industries Limited from a “sell” rating to a “hold” rating in a report on Monday, April 17th. Citigroup Inc. dropped their target price on shares of Teva Pharmaceutical Industries Limited from $47.00 to $42.00 and set a “buy” rating on the stock in a report on Tuesday, April 25th. Wells Fargo & Company restated a “market perform” rating on shares of Teva Pharmaceutical Industries Limited in a report on Saturday, April 29th. Finally, Maxim Group set a $35.00 target price on shares of Teva Pharmaceutical Industries Limited and gave the stock a “hold” rating in a report on Thursday, May 11th. One equities research analyst has rated the stock with a sell rating, twenty-two have issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $39.19.

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded down 6.917% during trading on Monday, hitting $19.175. The stock had a trading volume of 60,059,358 shares. The stock has a 50 day moving average of $32.05 and a 200 day moving average of $32.28. The firm has a market cap of $19.48 billion, a PE ratio of 245.833 and a beta of 0.46. Teva Pharmaceutical Industries Limited has a 52-week low of $18.82 and a 52-week high of $55.45.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing the Zacks’ consensus estimate of $1.06 by $0.07. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The firm had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.72 billion. During the same quarter in the previous year, the company earned $1.25 EPS. The company’s quarterly revenue was up 12.9% compared to the same quarter last year. On average, equities analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.44 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This news story was reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/07/barclays-plc-cuts-teva-pharmaceutical-industries-limited-nyseteva-price-target-to-23-00.html.

A number of hedge funds have recently made changes to their positions in the stock. Renaissance Technologies LLC boosted its position in Teva Pharmaceutical Industries Limited by 122.4% in the first quarter. Renaissance Technologies LLC now owns 4,817,763 shares of the company’s stock worth $154,602,000 after buying an additional 2,651,900 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. boosted its position in Teva Pharmaceutical Industries Limited by 405,409.9% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,435,505 shares of the company’s stock worth $46,065,000 after buying an additional 1,435,151 shares during the last quarter. Sei Investments Co. boosted its position in Teva Pharmaceutical Industries Limited by 103.6% in the second quarter. Sei Investments Co. now owns 1,721,466 shares of the company’s stock worth $57,188,000 after buying an additional 875,789 shares during the last quarter. Ameriprise Financial Inc. boosted its position in Teva Pharmaceutical Industries Limited by 142.2% in the first quarter. Ameriprise Financial Inc. now owns 1,288,571 shares of the company’s stock worth $41,349,000 after buying an additional 756,441 shares during the last quarter. Finally, Commerzbank Aktiengesellschaft FI boosted its position in Teva Pharmaceutical Industries Limited by 370.6% in the first quarter. Commerzbank Aktiengesellschaft FI now owns 929,084 shares of the company’s stock worth $29,814,000 after buying an additional 731,666 shares during the last quarter. Institutional investors own 56.27% of the company’s stock.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.